Healthcare

Image

Global Plasma Fractionation Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Report
  • Feb 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Plasma Fractionation Market, By Product Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Products), Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato- Oncology, Rheumatology and Others),  Processing Technology (Ion- Exchange Chromatography, Affinity Chromatography, Cryopreservation, Ultrafiltration and Microfiltration), Mode (Modern Plasma Fractionation and Traditional Plasma Fractionation), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutions, and Others), Distribution Channel (Direct Tenders, Third Party Distribution, and Others) – Industry Trends and Forecast to 2031.

Plasma Fractionation Market

Plasma Fractionation Market Analysis and Size

The plasma fractionation market encompasses modern and traditional techniques. Modern plasma fractionation utilizes advanced technologies such as chromatography and filtration to isolate specific plasma components with enhanced purity and yield. In contrast, traditional fractionation employs methods such as precipitation and centrifugation. Instances of modern techniques include the use of monoclonal antibodies for specific protein isolation, while traditional methods include cold ethanol precipitation for general plasma fractionation.

Data Bridge Market Research analyses that the global plasma fractionation market, which was USD 29,259.96 million in 2023, is expected to reach USD 48,425.11 million by 2031, at a CAGR of 6.5% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Plasma Fractionation Market Scope and Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Products), Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato- Oncology, Rheumatology and Others),  Processing Technology (Ion- Exchange Chromatography, Affinity Chromatography, Cryopreservation, Ultrafiltration and Microfiltration), Mode (Modern Plasma Fractionation and Traditional Plasma Fractionation), End User (Hospitals and Clinics, Clinical Research Laboratories, Academic Institutions, and Others), Distribution Channel (Direct Tenders, Third Party Distribution, and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), CSL Plasma (Australia), Japan Blood Products Organization (Japan), China Biologic Products Holdings, Inc. (China), LFB SA (France), Green Cross Corp. (South Korea), Shanghai RAAS (China), Baxter (U.S.), Bio Products Laboratory Ltd. (U.K.), Novasep Holding SAS (France), Pall Corporation (U.S.), KabaFusion (U.S.), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Bharat Serums and Vaccines Limited (India), SK Plasma (South Korea), Kedrion S.p.A (Italy), Sanquin (Netherlands), Biotest AG (Germany), Merck KGaA (Germany), ADMA Biologics, Inc. (U.S.), Boccard (France), Intas Pharmaceuticals Ltd. (India), CENTURION Ilaç Sanayi ve Ticaret A.S. (Turkey)

Market Opportunities

  • Advancements in Purification Techniques for Plasma Fractionation
  • Collaborations with Healthcare Providers for Plasma Supply

Market Definition

Plasma fractionation is a process used to separate various components of blood plasma, including proteins and other biological substances, for therapeutic purposes. Through fractionation, plasma-derived products such as immunoglobulins, albumin, and clotting factors are isolated and purified for use in treating various medical conditions, including immune deficiencies and bleeding disorders.

Global Plasma Fractionation Market Dynamics

Drivers

  • Growing Geriatric Population Requiring Plasma Products

Elderly individuals often require plasma-derived biopharmaceuticals to treat various medical conditions, including immune deficiencies and coagulation disorders, which become more prevalent with age. This demographic trend significantly amplifies the need for plasma fractionation, as the elderly population continues to grow globally, emphasizing the critical role of plasma products in geriatric healthcare.

  • Government Initiatives to Support Plasma Fractionation

Many governments implement policies and provide funding to encourage plasma donation, streamline plasma collection processes, and ensure the availability of plasma-derived products. These initiatives aim to enhance public health by addressing the increasing demand for plasma products and improving access to essential therapies. Consequently, government support acts as a key driver in sustaining growth and innovation within the plasma fractionation market.

Opportunities

  • Advancements in Purification Techniques for Plasma Fractionation

Innovative methods such as chromatography and filtration enhance the efficiency and yield of plasma-derived products while ensuring high purity and safety standards. These advancements enable manufacturers to produce a wider range of high-quality plasma products, meeting diverse clinical needs. Moreover, they present opportunities for companies to differentiate themselves in the market by offering superior products and expanding their customer base.

  • Collaborations with Healthcare Providers for Plasma Supply

Partnering with hospitals and clinics for plasma collection enhances access to raw materials, streamlines procurement processes, and fosters a reliable supply chain. Additionally, these collaborations present opportunities for market players to establish long-term relationships, expand their network, and tap into new sources of plasma, thereby strengthening their competitive position in the market.

Restraints/Challenges

  • Competition from Alternative Therapies Impede Market

Biosimilars offer similar therapeutic effects at potentially lower costs, enticing both patients and healthcare providers. This heightened competition can lead to pricing pressures and reduced market share for plasma-derived therapies. Consequently, companies may face decreased revenues and profitability, hindering investments in research and development. Thus, competition from alternative therapies presents a notable challenge to market growth.

  • Limited Availability of Plasma Donors for Collection

With fewer donors, there is a constrained supply of raw material for plasma-derived therapies, leading to production bottlenecks and potential shortages. This can disrupt manufacturing schedules, impacting product availability and revenue streams for companies. Moreover, increased competition for scarce donors may escalate collection costs, further squeezing profit margins and hindering market expansion.

This global plasma fractionation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global plasma fractionation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In October 2022, Grifols launched a new albumin purification and filling plant in Dublin, Ireland, as part of its global manufacturing and supply hub. This expansion enhances the company's capacity to produce albumin, a key component in plasma fractionation, contributing to meeting the growing demand in the plasma fractionation market
  • In September 2022, CSL Behring K.K. obtained approval from Japan's Ministry of Health, Labour and Welfare for Berinert S.C. Injection 2000. This lyophilized human C1-esterase inhibitor concentrate offers subcutaneous injection for preventing acute hereditary angioedema (HAE) attacks, displaying advancements in plasma derivatives for therapeutic applications in the plasma fractionation market
  • In May 2022, Terumo Blood and Cell Technologies inaugurated a $250 million production facility in Douglas County, Colorado. This 170,000-square-foot site aims to bolster healthcare contributions by manufacturing single-use collection sets for the FDA-approved Rika Plasma Donation System, catering to the increasing demand for source plasma collections in the plasma fractionation market
  • In April 2020, Grifols introduced a 3-ml vial for HyperRAB, a rabies immune globulin, into the plasma fractionation market. This expansion aimed to enhance treatment options for rabies cases globally. The plasma fractionation market involves isolating and purifying plasma components for therapeutic use in various medical conditions, meeting critical healthcare demands

Global Plasma Fractionation Market Scope

The global plasma fractionation market is segmented on the basis of product type, application, processing technology, mode, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Immunoglobulins
  • Intravenous
  • Subcutaneous
  • Coagulation Factor Concentrates
  • Factor IX
  • Factor VIII
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others
  • Albumin
  • Protease Inhibitors
  • Other Products

Application

  • Neurology
  • Immunology
  • Hematology
  • Critical Care
  • Pulmonology
  • Hemato- Oncology
  • Rheumatology
  • Others

Processing Technology

  • Ion- Exchange Chromatography
  • Affinity Chromatography
  • Cryopreservation
  • Ultrafiltration
  • Microfiltration

 Mode

  • Modern Plasma Fractionation
  • Traditional Plasma Fractionation

 End User

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic Institutions
  • Others

Distribution Channel

  • Direct Tenders
  • Third Party Distribution
  • Others

Global Plasma Fractionation Market Regional Analysis/Insights

The global plasma fractionation market is analysed and market size insights and trends are provided by product type, application, processing technology, mode, end user and distribution channel as referenced above.

The countries covered in the global plasma fractionation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the global plasma fractionation market, driven by rising usage of plasma-derived products and innovative developments. Within North America, the U.S. dominates with the highest CAGR, attributed to heightened awareness of plasma's benefits. This trend underscores the region's pivotal role in advancing plasma fractionation technologies and therapies.

In the Asia-Pacific region, China emerges as a dominant force in the global plasma fractionation market, fueled by surging demand and heightened health awareness. The nation's robust healthcare infrastructure and growing emphasis on human health underscore its pivotal role in driving advancements and meeting the rising demand for plasma fractionation products.

In Europe, Germany leads the market due to its large geriatric population and prevalence of immune deficiency diseases. These factors drive significant demand for plasma fractionation products, positioning Germany as a dominant player in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global plasma fractionation market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global plasma fractionation market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global plasma fractionation market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Plasma Fractionation Market Share Analysis

The global plasma fractionation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global plasma fractionation market.

Some of the major players operating in the global plasma fractionation market are:

  • Grifols, S.A. (Spain)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Octapharma AG (Switzerland)
  • CSL Plasma (Australia)
  • Japan Blood Products Organization (Japan)
  • China Biologic Products Holdings, Inc. (China)
  • LFB SA (France)
  • Green Cross Corp. (South Korea)
  • Shanghai RAAS (China)
  • Baxter (U.S.)
  • Bio Products Laboratory Ltd. (U.K.)
  • Novasep Holding SAS (France)
  • Pall Corporation (U.S.)
  • KabaFusion (U.S.)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Bharat Serums and Vaccines Limited (India)
  • SK Plasma (South Korea)
  • Kedrion S.p.A (Italy)
  • Sanquin (Netherlands)
  • Biotest AG (Germany)
  • Merck KGaA (Germany)
  • ADMA Biologics, Inc. (U.S.)
  • Boccard (France)
  • Intas Pharmaceuticals Ltd. (India)
  • CENTURION Ilaç Sanayi ve Ticaret A.S. (Turkey)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Plasma Fractionation Market size will be worth USD 48,425.11 million by 2031 during the forecast period.
The Plasma Fractionation Market growth rate is 6.5% during the forecast period.
The Growing Geriatric Population Requiring Plasma Products and Government Initiatives to Support Plasma Fractionation are the growth drivers of the Plasma Fractionation Market.
The product type, application, processing technology, mode, end user, and distribution channel are the factors on which the Plasma Fractionation Market research is based.
The major companies in the Plasma Fractionation Market are Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Octapharma AG (Switzerland), CSL Plasma (Australia), Japan Blood Products Organization (Japan), China Biologic Products Holdings, Inc. (China), LFB SA (France), Green Cross Corp. (South Korea), Shanghai RAAS (China), Baxter (U.S.), Bio Products Laboratory Ltd. (U.K.), Novasep Holding SAS (France), Pall Corporation (U.S.), KabaFusion (U.S.), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Bharat Serums and Vaccines Limited (India), SK Plasma (South Korea), Kedrion S.p.A (Italy), Sanquin (Netherlands), Biotest AG (Germany), Merck KGaA (Germany), ADMA Biologics, Inc. (U.S.), Boccard (France), Intas Pharmaceuticals Ltd. (India), CENTURION Ilaç Sanayi ve Ticaret A.S. (Turkey).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials